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Background: Obesity has been shown to be inversely associated with breast cancer risk in premenopausal women,
while increasing risk in postmenopausal women. However, the current evidence is largely based on studies in
Caucasian populations. Associations in women of African ancestry (AA), who have a higher prevalence of obesity,
have been evaluated in few studies and results suggest different effects.
Methods: We evaluated the impact of body size, body fat distribution, and body composition on breast cancer risk
among AA women (978 cases and 958 controls) participating in the Women’s Circle of Health Study, a multi-site
case–control study in New York City (NYC) and New Jersey (NJ). Cases were newly diagnosed with histologically
confirmed ductal carcinoma in situ or invasive breast cancer, age 20–75 yrs. In NYC, cases were recruited through
hospitals with the largest referral patterns for AA women and controls through random digit dialing (RDD). In NJ,
cases were identified in seven counties in NJ thorough the NJ State Cancer Registry, and controls through RDD and
community-based recruitment. During in-person interviews, questionnaires were administered and detailed
anthropometric measurements were obtained. Body composition was assessed by bioelectrical impedance analysis.
Results: BMI did not have a major impact on pre- or post-menopausal breast cancer, but was significantly
associated with reduced risk of ER-/PR- tumors among postmenopausal women (OR: 0.37; 95% CI: 0.15-0.96 for
BMI > 30 vs. BMI < 25). Furthermore, increased premenopausal breast cancer risk was found for higher waist and hip
circumferences after adjusting for BMI, with ORs of 2.25 (95% CI: 1.07-4.74) and 2.91 (95% CI: 1.39-6.10), respectively,
comparing the highest vs. lowest quartile. While ORs for higher fat mass and percent body fat among
postmenopausal women were above one, confidence intervals included the null value.
Conclusions: Our study suggests that in AA women BMI is generally unrelated to breast cancer. However, higher
waist and hip circumferences were associated with increased pre-menopausal breast cancer risk, while general
obesity was associated with decreased risk of ER-/PR- tumors. Larger studies are needed to confirm findings and to
evaluate the impact of obesity on breast cancer subtypes.
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In the United States, breast cancer is the most common
cancer in women excluding skin cancer and the second
leading cause of cancer mortality [1]. Rates vary consi-
derably by race/ethnicity [1]. While women of African
ancestry (AA) have lower incidence compared to those
of European descent (EA), incidence is higher for those
younger than 40 years [1]. AA women with breast can-
cer also experience the highest mortality rates for any
racial/ethnic groups [1]. Several factors, many related to
socio-economic status, have been proposed to explain
these differences in AA women, including poorer access
to screening, pre-existing conditions, suboptimal treat-
ment for breast cancer, lifestyle factors, and obesity [2].
AA women tend to have aggressive tumor characteristics
and more advanced tumors at diagnosis, which have also
been linked to obesity [3,4].
Obesity is a major public health concern in AA
women, with the prevalence of obesity (BMI ≥ 30) being
58.6% for “non-Hispanic black women” and 33.4% for
“non-Hispanic white women”, according to 2009–2010
National Health and Nutrition Examination Survey
(NHANES) data [5]. AA women also tend to have higher
waist circumference than EA women [4]. Excess body
fatness is a well-recognized risk factor for breast cancer,
with studies showing increased risk for postmenopausal
women and an inverse association in pre-menopausal
women [6]. However, there is growing evidence that this
relationship is complex, with the association varying by
race, age, HRT use, and possibly by hormone receptor
status [7]. Furthermore, the current evidence is largely
based on studies conducted in white women, with only a
few studies evaluating the role of measures of body fat-
ness, such as body mass, central adiposity, or percent
body fat, among AA women [7,8]. The evidence from
the few studies that evaluated the impact of BMI on
breast cancer risk in AA women is generally inconsistent
but suggests different effects (reviewed in [3,7,8]). Al-
though some studies have indicated increased breast
cancer risk associated with higher waist circumference
and waist-to-hip ratio in pre-menopausal women [9], the
overall evidence independent of BMI remains uncertain.
The impact of body composition on breast cancer risk
in AA women is unknown. Therefore, we evaluated
the impact of body mass index, body fat distribution and
body composition on breast cancer risk among pre-
and postmenopausal AA women participating in the
Women’s Circle of Health Study.
Methods
Study population
The Women’s Circle of Health Study (WCHS) is a
multi-site case–control study in New York City (NYC)
and New Jersey (NJ) specifically designed to evaluategenetic and lifestyle risk factors for early/aggressive
breast cancer and to compare the distribution of these
factors in AA and EA women. The study design has
been described in detail elsewhere [10]. In brief, cases
were self-identified AA and EA women, 20–75 years of
age, and able to understand and read English with no
previous history of cancer other than non-melanoma
skin cancer, and diagnosed within 9 months with pri-
mary, histologically confirmed invasive breast cancer or
ductal carcinoma in situ (DCIS). Controls had the same
eligibility criteria and no history of cancer and were
identified, recruited, and interviewed during the same
time period as the cases.
In NYC, cases were identified through collaborations
with hospitals in Manhattan, Bronx, Brooklyn, and
Queens with the largest referral patterns for AA women.
Controls in NYC were ascertained by RDD, using the
telephone exchanges (area code plus three-digit prefixes)
of breast cancer cases who received medical care at the
participating hospitals in previous years for sampling,
frequency matched by 5-year age groups and race. In
New Jersey, cases were identified through the NJ
State Cancer Registry (NJSCR), using rapid case ascer-
tainment in seven counties (Bergen, Essex, Hudson,
Mercer, Middlesex, Passaic, and Union), with extension
Monmouth and Burlington counties in 2012. Controls
were identified by RDD in NYC and NJ, frequency
matched by age group and county of residence to the
cases. In NJ, controls were also recruited through com-
munity sources, as described in detail elsewhere [11].
Data collection
After confirming eligibility, an in-person interview was
scheduled at the participants’ homes or a mutually
agreed upon location. All interviewers underwent rigo-
rous standardized training and testing before they were
allowed to start conducting interviews and anthropomet-
ric measurements. Informed consent was obtained in
person at the visit before data collection began. During
the in-person interview several questionnaires were
completed, body measurements taken, and biospecimens
collected.
The WCHS survey instrument covered established and
suspected risk factors for breast cancer, including family
history, reproductive and menstrual history, hormone
use, alcohol intake and smoking, occupational history,
and physical activity. Women were also asked to report
their weight and height one year before diagnosis
(for cases) or reference date (for controls), and at several
times during their life.
Anthropometric measurements were taken at the end
of the visit using a standardized protocol based on
the Women’s Interview Study of Health [12] and mea-
suring instruments. Participants were asked to wear light
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jewelry. Standing height was measured once to the
nearest 0.1 cm. Waist and hip circumferences were
measured twice to the nearest 0.1 cm by placing the
measuring tape around the waist covering the umbilicus
(for waist) or at the maximum extension of the buttocks
(for hip) in a horizontal plane. If the difference between
the first and second measurement was greater than
2 cm, a third measurement was taken. The two (or
three) measurements were averaged for analyses. While
there is no uniformly accepted protocol for measuring
waist and hip circumference, repeated measurements
have been shown to reduce measurement error and a
clinically relevant change in waist circumference has
been estimated to range between 3.0 and 6.8 cm [13].
Therefore, a tolerance limit of 2 cm, below this clinically
relevant range, was used. Body composition (lean and fat
mass, percent body fat) was measured by bioelectrical
impedance analysis using a Tanita® TBF-300A scale.
Weight was measured once using the Tanita scale.
A total of 979 AA cases and 958 AA controls com-
pleted the interview. Height and/or weight measure-
ments were not available for 25 cases and 13 controls
because the participants refused (n = 24), were more
than 3 months pregnant (n = 2), or for other reasons
(e.g., physical impairments) (n = 12). Because we found
high correlation between BMI based on measurements
and based on self-reported weight and height (r = 0.92),
missing values for height and/or weight were substituted
with self-reported values when available to compute the
final BMI variable used to compute risk estimates. One
case was excluded because she did not have measured
or self-reported weight and height, leaving 978 cases
and 958 controls for analyses.
The study was approved by the Institutional Review
Boards at the Cancer Institute of New Jersey (now
Rutgers Cancer Institute of New Jersey), Mount Sinai
School of Medicine (now the Icahn School of Medicine
at Mount Sinai), and Roswell Park Cancer Institute and
all participants provided written informed consent be-
fore participating in the study.
Statistical analyses
All analyses were conducted separately in pre- and post-
menopausal women. BMI was computed as weight in
kilograms (kg) divided by the square of height in meters
(m). Self-reported BMI one year prior to reference date
(diagnosis date for cases and comparable date for con-
trols) was calculated using measured height at interview
and self-reported weight, except for 26 women for
whom measured height was missing and instead, self-
reported height was used. Fat mass index and fat free
mass index were calculated as fat mass or fat free mass
in kg, respectively, divided by the square of height inmeters. BMI was categorized according to the World
Health Organization (WHO) International Classification.
For all other variables we used quartiles, based on the
distribution of all controls combined. We used the same
cutpoints in the two subgroups by menopausal status to
be able to compare risk estimates across categories.
Distributions of selected risk factors between cases
and controls stratified by menopausal status were
compared using chi-square tests and means compared
using the t-test. Multivariable unconditional logistic re-
gression was used to estimate odds ratios (OR) and 95%
confidence intervals (CI), controlling for relevant con-
founders. Tests for trend were derived by assigning the
median value to each category. Covariates considered
included age, ethnicity (Hispanic vs. not Hispanic),
country of origin (United States, Caribbean countries,
other), education, family history of breast cancer, history
of benign breast disease, age at menarche, age at meno-
pause, parity, breastfeeding (never/ever), age at first
birth, hormone replacement therapy use (never/ever),
oral contraceptive use (never/ever), years since meno-
pause (for analyses of body composition), and BMI in
young adulthood. We also controlled for waist circum-
ference when evaluating relationships with BMI, and
BMI when evaluating relationships with body fat distri-
bution to assess the potentially independent effects of
general and central obesity, respectively.
Possible effect modification by hormone receptor
status was evaluated by conducting stratified analyses
according to the major subtypes (ER+/PR + and ER-/
PR-) in addition to conducting case-case analyses to
estimate risk of ER-/PR- tumors compared to ER+/PR+
tumors. Analyses were repeated excluding HRT users
and non-invasive tumors, as well as community controls.
A finding with a p value of less than 0.05 was considered
statistically significant. SAS version 9.2 (SAS Institute,
Cary NC) was used for analyses.
Results
Selected characteristics for study participants by meno-
pausal status are shown in Table 1. For both pre- and
post-menopausal women, cases tended to be slightly
older and have fewer years of education than controls,
while family history of breast cancer, history of benign
breast disease, and use of HRT were more common in
cases than controls in both pre- and post-menopausal
women.
As shown in Table 2, there was little indication that
BMI played a major role in breast cancer risk in AA
women. ORs for both pre- and post-menopausal women
with BMI > 40 were below one, but the confidence inter-
vals included the null. We also evaluated BMI based on
self-reported weight one year before reference date and
measured height at interview, with no clear evidence of
Table 1 Selected characteristics among women of African ancestry in the Women’s Circle of Health Study
Pre-menopausal Post-menopausal
Cases Controls p value Cases Controls p value
(n = 469) (n = 482) (n = 509) (n = 476)
n (%) n (%) n (%) n (%)
Age (yrs)
Mean ± SD 43.93 ± 6.8 42.65 ± 7.1 0.005 59.68 ± 6.7 57.70 ± 6.1 <0.0001
Education
<High school 57 (12.2) 67 (13.9) 0.07 90 (17.7) 57 (12) 0.003
High school graduate 133 (28.4) 112 (23.2) 165 (32.4) 130 (27.3)
Some college 136 (29) 120 (24.9) 122 (24) 159 (33.4)
College graduate 91 (19.4) 121 (25.1) 81 (15.9) 74 (15.6)
Post-graduate degree 52 (11.1) 62 (12.9) 51 (10) 56 (11.8)
Marital Status
Married 184 (39.2) 176 (36.5) 0.05 158 (31.1) 155 (32.7) 0.19
Living as married 8 (1.7) 9 (1.9) 6 (1.2) 11 (2.3)
Widowed 10 (2.1) 14 (2.9) 88 (17.3) 57 (12)
Separated 35 (7.5) 22 (4.6) 38 (7.5) 38 (8)
Divorced 71 (15.1) 55 (11.4) 102 (20.1) 93 (19.6)
Single 161 (34.3) 206 (42.7) 116 (22.8) 120 (25.3)
Country of origin
United States 297 (63.3) 378 (78.4) <0.0001 404 (79.4) 391 (82.1) 0.54
Caribbean 131 (27.9) 75 (15.6) 74 (14.5) 61 (12.8)
Other 41 (8.7) 29 (6) 31 (6.1) 24 (5)
Ethnicity
Hispanic 29 (6.2) 14 (2.9) 0.02 16 (3.1) 12 (2.5) 0.56
Non-Hispanic 440 (93.8) 468 (97.1) 493 (96.9) 464 (97.5)
Age at menarche (yrs)
<12 139 (29.6) 144 (29.9) 0.52 152 (29.9) 121 (25.5) 0.23
12-13 220 (46.9) 211 (43.8) 221 (43.4) 229 (48.2)
>13 110 (23.5) 127 (26.4) 136 (26.7) 125 (26.3)
Age at menopause (yrs)
≤45 70 (14.1) 78 (16.5) <0.001
46-49 64 (12.9) 107 (22.7)
50-54 311 (62.5) 242 (51.3)
≥55 53 (10.6) 45 (9.5)
Parity (livebirths)
0 87 (18.6) 82 (17) 0.17 67 (13.2) 75 (15.8) 0.17
1-2 257 (54.8) 241 (50) 242 (47.5) 235 (49.4)
3-4 104 (22.2) 127 (26.4) 137 (26.9) 126 (26.5)
≥5 21 (4.5) 32 (6.6) 63 (12.4) 40 (8.4)
Age at first birth (yrs)
Nulliparous 87 (18.6) 82 (17) 0.32 67 (13.2) 75 (15.8) 0.41
≤19 127 (27.1) 148 (30.7) 190 (37.3) 168 (35.4)
20-24 108 (23.1) 117 (24.3) 131 (25.7) 120 (25.3)
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Table 1 Selected characteristics among women of African ancestry in the Women’s Circle of Health Study (Continued)
25-30 89 (19) 70 (14.5) 82 (16.1) 64 (13.5)
≥31 57 (12.2) 65 (13.5) 39 (7.7) 47 (9.9)
Breastfeeding
Nulliparous 87 (18.6) 82 (17) 0.32 67 (13.2) 75 (15.8) 0.34
Never (among parous) 158 (33.7) 185 (38.4) 267 (52.5) 230 (48.3)
Ever 224 (47.8) 215 (44.6) 175 (34.4) 171 (35.9)
Family history
No 370 (78.9) 416 (86.3) 0.003 365 (71.7) 389 (81.7) <0.001
Yes 99 (21.1) 66 (13.7) 144 (28.3) 87 (18.3)
History of benign breast disease
Never 333 (71.3) 393 (81.7) <0.001 330 (64.8) 345 (72.5) 0.01
Ever 134 (28.7) 88 (18.3) 179 (35.2) 131 (27.5)
HRT use
Never 449 (96.2) 467 (96.9) 0.53 375 (74.4) 378 (79.8) 0.05
Ever 18 (3.9) 15 (3.1) 129 (25.6) 96 (20.3)
Oral contraceptive use
Never 175 (37.3) 189 (39.2) 0.55 212 (41.7) 220 (46.4) 0.14
Ever 294 (62.7) 293 (60.8) 296 (58.3) 254 (53.6)
Smoking status
Never smoker 297 (71.4) 287 (60.7) <0.001 219 (53.4) 226 (52.3) 0.13
Former smoker 62 (14.9) 76 (16.1) 127 (31) 117 (27.1)
Current smoker 57 (13.7) 110 (23.3) 64 (15.6) 89 (20.6)
SD standard deviation.
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after adjusting for waist circumference (Table 2).
When we evaluated measures of body fat distribution
in pre- and post-menopausal women (Table 3), there
was a weak positive association for postmenopausal
women with higher waist-to-hip ratio (WHR) but the
confidence intervals included the null value (OR: 1.43;
95% CI: 0.95-2.18 comparing highest to lowest quartile).
However, after adjusting for BMI, a strong association
emerged with waist and hip circumferences for pre-
menopausal women, with an OR for waist circumference
of 2.25 (95% CI: 1.07-4.74) for the highest vs. lowest
quartile and an estimated 10% increase in risk per 5 cm
increment in waist circumference. For hip circumfe-
rence, after adjusting for BMI, the OR for the highest vs.
lowest quartile was 2.91 (95% CI: 1.39-6.10), with a 12%
increase in risk per 5 cm increment in hip circumfe-
rence. Among post-menopausal women, no clear associ-
ations were observed. No association was also found for
pre- or postmenopausal women with any of the body
composition measures considered: fat mass, fat free
mass, percent body fat, fat mass index, and fat free mass
index (Table 4).
Restricting analyses to invasive cases led to essentially
the same results (data not shown). Because it has beensuggested that the relationship between BMI and breast
cancer risk may be limited to non-HRT users [14,15], we
also repeated analyses excluding HRT users (Table 5).
Among non-HRT users, while there was no association
with BMI, other adiposity measures tended to increase
risk but most estimates were not significant, with the
exception of hip circumference among pre-menopausal
women, which significantly increased breast cancer risk.
Excluding community controls did not substantially
change estimates.
We also explored possible effect modification by the
major breast cancer subtypes based on hormone recep-
tor status: ER+/PR+ and ER-/PR- (Tables 6 and 7). The
major findings were a strong association with hip cir-
cumference for ER+/PR+ tumors for pre-menopausal
women and an inverse association with BMI for ER-/PR-
tumors for post-menopausal women. No other clear pat-
terns emerged from these analyses.
Discussion
In this study we found that BMI did not play a major
role on breast cancer among AA women, except for a
significant inverse association for ER-/PR- tumors in
post-menopausal women. Furthermore, higher waist and
hip circumferences increased pre-menopausal breast
Table 2 Association of body size and breast cancer risk in women of African ancestry, Women’s Circle of Health Study
Pre-menopausal Post-menopausal
Cases/Controls OR1 95% CI OR2 95% CI Cases/Controls OR1 95% CI OR2 95% CI
Current BMI*
Underweight/Normal (<25) 102/103 Ref Ref 74/68 Ref Ref
Overweight (25–29.99) 150/142 1.02 0.70–1.49 1.05 0.70–1.57 131/132 0.93 0.60–1.44 0.93 0.59–1.47
Obese (≥30) 217/237 0.89 0.61–1.28 0.92 0.54–1.56 304/276 0.98 0.66–1.45 1.00 0.58–1.72
p for trend 0.40 0.65 0.94 0.86
Current BMI*
Underweight/Normal (<25) 102/103 Ref Ref 74/68 Ref Ref
Pre–obese (25–29.99) 150/142 1.01 0.69–1.48 0.98 0.64–1.49 131/132 0.93 0.60–1.44 0.88 0.55–1.41
Obese Class I (30–34.99) 111/94 1.06 0.70–1.61 0.93 0.54–1.62 146/121 1.08 0.70–1.68 0.98 0.56–1.72
Obese Class II (35–39.99) 50/68 0.71 0.43–1.17 0.62 0.31–1.26 94/89 0.90 0.56–1.44 0.80 0.41–1.58
Obese Class III (≥40) 56/75 0.79 0.49–1.29 0.64 0.26–1.56 64/66 0.89 0.53–1.48 0.74 0.31–1.78
p for trend 0.17 0.20 0.65 0.47
BMI one year before reference date**
Underweight/Normal (<25) 115/113 Ref Ref 66/77 Ref Ref
Overweight (25–29.99) 138/143 0.86 0.59–1.25 0.90 0.61–1.33 147/140 1.27 0.82–1.96 1.32 0.84–2.07
Obese (≥30) 214/221 0.91 0.63–1.30 1.00 0.62–1.62 293/254 1.27 0.85–1.89 1.46 0.87–2.44
p for trend 0.74 0.88 0.41 0.22
BMI one year before reference date**
Underweight/Normal (<25) 115/113 Ref Ref 66/77 Ref Ref
Pre-obese (25–29.99) 138/143 0.86 0.59–1.25 0.87 0.58–1.29 147/140 1.27 0.82–1.96 1.32 0.83–2.08
Obese Class I (30–34.99) 121/92 1.17 0.77–1.76 1.16 0.71–1.90 143/129 1.23 0.79–1.90 1.34 0.80–2.27
Obese Class II (35–39.99) 43/73 0.55 0.33–0.90 0.54 0.28–1.02 87/55 1.70 1.02–2.82 1.97 1.02–3.82
Obese Class III (≥40) 50/56 0.93 0.56–1.54 0.93 0.43–2.00 63/70 0.98 0.58–1.64 1.19 0.55–2.55
p for trend 0.39 0.61 0.86 0.64
*BMI measured at interview. **Based on self-reported weight one year before reference date and measured height at interview.
OR1: Adjusted for age, ethnicity, country of origin (United States, Caribbean, other), education, family history of breast cancer, history of benign breast disease,
age at menarche, age at menopause (for postmenopausal women), parity (continuous), breastfeeding (yes/no), age at first birth, HRT use (ever/never), OC use
(ever/never). OR2: Further adjusted for waist circumference.
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suggestion of increased risk with higher fat mass and
percent body fat among post-menopausal women, confi-
dence intervals included the null value.
Very few studies have previously evaluated the role of
recent BMI on breast cancer risk among AA (reviewed
in [3,7,8]) and in general, previous findings are in agree-
ment with ours. As in our study, no association with
pre-menopausal breast cancer was reported in six other
case–control studies [16-21] and one cohort study [22].
For post-menopausal breast cancer, results have been in-
consistent. Similar to our results, no increased risk was
reported in most of these studies, with an inverse associ-
ation suggested in four of the case–control studies
[16,18,23,24], weak and non-significant association in
another case–control study [21] and in the Multi-Ethnic
Cohort [25], and no association in the Black Women’s
Health Study cohort [22]. Only two case–control studies
have reported an increased risk among AA women[17,19]. Two additional studies conducted in Nigeria
[26] and Barbados [27] reported no association with
BMI. One of the most striking results from our study is
the strong inverse association with BMI for ER-/PR-
tumors among post-menopausal women. Similar inverse
association was suggested in the two studies that presen-
ted stratified analyses by receptor status, the Women’s
CARE Study [21] and in the Black Women’s Health Study
[22]. However, confidence intervals in these two studies
included the null, and, therefore, more studies are needed
to understand the role of BMI on ER-/PR- tumors and on
postmenopausal breast cancer in general.
In contrast to the findings for general obesity, we found
a strong association with waist and hip circumferences,
after adjusting for BMI in pre-menopausal women. While
studies have typically used WHR to measure body fat
distribution, waist circumference has been shown to be a
better marker of central obesity than WHR in AA women
[4]. Other studies, largely conducted among EA women,
Table 3 Body fat distribution measures and breast cancer risk
Pre-menopausal Post-menopausal
Cases/Controls OR1 95% CI OR2 95% CI Cases/Controls OR1 95% CI OR2 95% CI
Waist to hip ratio
≤0.82 123/144 Ref Ref 65/93 Ref Ref
0.83–0.87 128/120 1.14 0.79–1.65 1.20 0.82–1.74 146/117 1.58 1.03–2.40 1.59 1.04–2.42
0.88–0.92 105/121 0.98 0.66–1.44 1.07 0.72–1.60 120/116 1.22 0.79–1.88 1.24 0.80–1.92
>0.92 104/93 1.19 0.80–1.79 1.38 0.89–2.12 169/144 1.43 0.95–2.18 1.48 0.97–2.26
p for trend 0.55 0.22 0.33 0.27
Waist circumference (cm)
≤87.88 137/143 Ref Ref 87/94 Ref Ref
87.89–97.75 124/119 1.02 0.70–1.46 1.26 0.85–1.88 119/118 1.07 0.71–1.61 1.13 0.73–1.76
97.76–110.25 107/116 0.93 0.64–1.37 1.47 0.88–2.44 154/121 1.35 0.90–2.02 1.51 0.92–2.48
>110.25 92/100 0.98 0.65–1.48 2.25 1.07–4.74 140/137 1.00 0.67–1.50 1.23 0.64–2.34
p for trend 0.84 0.04 0.96 0.48
Per 5 cm 0.99 0.95–1.03 1.10 1.00–1.22 1.00 0.96–1.04 1.03 0.94–1.13
Hip circumference (cm)
≤103.18 127/138 Ref Ref 107/99 Ref Ref
103.19–111.63 133/111 1.25 0.86–1.81 1.60 1.07–2.39 129/126 0.99 0.67–1.47 0.99 0.65–1.51
111.64–123.15 101/116 1.00 0.68–1.46 1.60 0.98–2.60 145/122 1.16 0.79–1.72 1.16 0.71–1.89
>123.15 100/113 1.07 0.72–1.59 2.91 1.39–6.10 119/123 0.88 0.59–1.31 0.87 0.45–1.71
p for trend 0.99 0.01 0.54 0.69
Per 5 cm 0.98 0.93–1.03 1.12 0.99–1.27 0.98 0.94–1.03 0.97 0.87–1.08
OR1: Adjusted for age, ethnicity, country of origin (United States, Caribbean, other), education, family history of breast cancer, history of benign breast disease,
age at menarche, age at menopause (for postmenopausal women), parity (continuous), breastfeeding (yes/no), age at first birth, HRT use (ever/never), OC use
(ever/never). OR2: Further adjusted for BMI.
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breast cancer associated with central adiposity, mostly
measured with WHR [4], although there is some incon-
sistency across studies particularly for WHR [6] and no
association for premenopausal breast cancer [4]. However,
a recent meta-analysis reported that after adjusting for
BMI, the association with WHR for postmenopausal
breast cancer disappeared, while introducing an associ-
ation for pre-menopausal breast cancer [9]. To our
knowledge, only the Carolina Breast Cancer Study
(CBCS) [18], the Black Women’s Health Study (BWHS)
[22], the San Francisco Bay Area Breast Cancer Study
(in pre-menopausal women) [20], and the Nigeria Breast
Cancer Study (NBCS) [28] have reported on the associ-
ation in AA women. For pre-menopausal breast cancer,
two of the case–control studies (CBCS and NBCS) [18,28]
found elevated risk with higher WHR [18,28] and waist
circumference adjusted for BMI [28]. However, in contrast
to our findings, an inverse association with hip circumfe-
rence adjusted for BMI was found in the NBCS [28]. No
association with WHR or waist circumference was found
in the Bay Area case–control study [20] or the BWHS [22].
For post-menopausal breast cancer, the two case–control
studies [18,28] suggested increased risk with centralobesity. In CBCS [18], there was a suggestion of increased
risk with higher WHR after adjusting for BMI but the
confidence interval include the null, similar to our fin-
dings. The NBCS [28] found increased risk for high
waist circumference and WHR independent of BMI, and
an inverse association with hip circumference, which is
in the same direction as our results. There was little evi-
dence of an association with self-reported waist circum-
ference or WHR in the BWHS [22].
To examine breast cancer relationships with obesity
and central adiposity independently, our analytic strategy
involved generating mutually adjusted risk estimates. Be-
cause measures of central obesity (e.g., waist circumfe-
rence) and BMI in general tend to be correlated, however,
there is potential for multicollinearity and inadvertent
introduction of bias [29]. To ensure that this is not a
concern, we carried out additional analyses to examine
the impact of assessing BMI simultaneously with waist
circumference, and determine whether issues with
multicollinearity were impacting our risk estimates. Since
the outcome is binary, the options for testing multicollinearity
such as variance inflation factor (VIF) and tolerance,
which are applied to continuous outcomes, do not directly
apply. However, a general recommendation to check
Table 4 Body composition measures and breast cancer
Pre-menopausal Post-menopausal
Cases/Controls OR1 95% CI OR2 95% CI Cases/Controls OR1 95% CI OR2 95% CI
Fat mass (kg)
≤25.3 128/125 Ref Ref 101/102 Ref Ref
25.4–34.1 131/116 1.08 0.74–1.56 1.24 0.82–1.87 126/107 1.16 0.78–1.74 1.34 0.86–2.07
34.2–44.3 96/100 0.92 0.62–1.37 1.19 0.70–2.03 124/123 0.94 0.63–1.40 1.21 0.72–2.04
>44.3 87/114 0.82 0.54–1.23 1.39 0.61–3.14 120/110 1.05 0.70–1.57 1.69 0.82–3.49
p for trend 0.24 0.49 0.93 0.22
Fat free mass (kg)
≤44.1 112/108 Ref Ref 130/118 Ref Ref
44.2–48 121/125 0.94 0.64–1.39 1.04 0.70–1.55 134/99 1.28 0.87–1.88 1.32 0.88–1.96
48.1–52.6 106/99 1.00 0.67–1.51 1.24 0.78–1.98 107/124 0.87 0.59–1.27 0.92 0.59–1.43
>52.6 103/123 0.84 0.57–1.26 1.32 0.70–2.47 101/101 0.96 0.65–1.43 1.05 0.61–1.83
p for trend 0.44 0.35 0.47 0.88
Percent body fat
≤35.9 145/137 Ref Ref 93/94 Ref Ref
36–41.6 118/118 0.92 0.64–1.33 1.02 0.69–1.52 123/107 1.14 0.75–1.71 1.27 0.83–1.96
41.7–46.5 96/104 0.88 0.60–1.30 1.07 0.67–1.72 119/124 0.85 0.57–1.29 1.05 0.65–1.70
>46.5 83/106 0.82 0.55–1.23 1.22 0.62–2.42 137/119 1.09 0.73–1.63 1.59 0.87–2.93
p for trend 0.32 0.65 0.98 0.26
Fat mass index
≤9.37 128/129 Ref – – 86/96 Ref - -
9.38–12.78 138/119 1.09 0.75–1.58 - - 124/104 1.39 0.92–2.11 - -
12.79–16.77 93/98 0.95 0.63–1.42 - - 140/127 1.13 0.75–1.70 - -
>16.77 83/109 0.80 0.53–1.21 - - 121/115 1.10 0.72–1.66 - -
p for trend 0.35 - - 0.58 - -
Fat free mass index - - - -
≤16.64 126/118 Ref - - 123/106 Ref - -
16.65-18.04 116/121 0.88 0.60–1.28 - - 108/104 0.94 0.63–1.40 - -
18.05–19.80 99/99 0.85 0.57–1.28 - - 129/124 0.89 0.60–1.30 - -
>19.80 101/117 0.81 0.54–1.21 - - 112/108 0.86 0.58–1.28 - -
p for trend 0.33 - - 0.45 - -
Fat mass index: fat mass in kg/(height in m)2; Fat Free Mass index: fat free mass in kg/(height in m)2 OR1: Adjusted for age, ethnicity, country of origin, education,
family history of breast cancer, history of benign breast disease, age at menarche, years since menopause (for postmenopausal women), parity (continuous),
breastfeeding (yes/no), age at first birth, HRT use (never/ever), OC use (never/ever). OR2: Further adjusted for BMI.
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http://www.biomedcentral.com/1471-2407/13/475multicollinearity in logistic models is to run a similar
model in linear regression and obtain collinearity sta-
tistics [30]. When we obtained tolerance and VIF sta-
tistics using this approach, the VIFs for BMI and
waist circumference were over 4, indicating that the
respective standard errors of these variables are twice
as inflated relative to the absence of multicollinearity.
However, when we checked the standard errors of these
two variables in the logistic model, they were 0.01 for waist
circumference and 0.02 for BMI, indicating that there
was no substantial inflation, and suggesting that
multicollinearity, if any, was not a severe issue in this model.Another sign of multicollinearity is if the global model is
significant but none of the individual covariates are sig-
nificant. In our model that included waist circumference
and BMI, the coefficients of both variables were statisti-
cally significant (p ≤ 0.05). Lastly, we obtained significant
associations both when waist circumference was treated
in linear and non-linear forms. Put together, these results
point to an issue of confounding rather than moderate or
severe multicollinearity. In general, when waist circumfe-
rence is included in the model as independent variables
with BMI as a covariate, BMI becomes more of an index
of lean mass than fatness in this multivariate model
Table 5 Association of body size and breast cancer risk among non-HRT users (excluding n = 267 HRT users)
Pre-menopausal Post-menopausal
Cases/Controls OR1 95% CI OR2 95% CI Cases/Controls OR1 95% CI OR2 95% CI
Current BMI*
Underweight/Normal (<25) 96/102 Ref Ref 55/53 Ref Ref
Overweight (25–29.99) 147/136 1.09 0.74–1.61 1.12 0.74–1.69 86/107 0.76 0.46–1.26 0.77 0.46–1.31
Obese (≥30) 206/229 0.91 0.63–1.32 0.92 0.54–1.58 234/218 0.97 0.62–1.52 1.05 0.57–1.95
p for trend 0.41 0.60 0.56 0.49
% Body Fat
≤35.9 139/133 Ref Ref 69/73 Ref Ref
36–41.6 112/114 0.90 0.62–1.31 0.98 0.65–1.46 85/86 1.05 0.66–1.68 1.18 0.72–1.95
41.7–46.5 94/101 0.89 0.60–1.32 1.03 0.63–1.66 90/95 0.87 0.54–1.39 1.06 0.61–1.84
>46.5 79/103 0.81 0.53–1.22 1.08 0.54–2.17 102/96 1.03 0.65–1.64 1.49 0.74–2.99
p for trend 0.31 0.88 0.94 0.38
Waist to hip ratio
≤0.82 118/144 Ref Ref 52/70 Ref Ref
0.83–0.87 122/113 1.21 0.83–1.77 1.27 0.87–1.86 97/94 1.16 0.72–1.88 1.17 0.72–1.90
0.88–0.92 100/116 1.02 0.69–1.52 1.11 0.74–1.67 78/88 0.97 0.58–1.59 0.99 0.60–1.64
>0.92 100/90 1.22 0.80–1.84 1.38 0.89–2.14 140/121 1.29 0.81–2.06 1.34 0.83–2.16
p for trend 0.51 0.22 0.35 0.28
Waist circumference (cm)
≤87.88 130/140 Ref Ref 62/75 Ref Ref
87.89–97.75 120/114 1.04 0.71–1.50 1.25 0.83–1.88 82/91 1.04 0.64–1.67 1.18 0.70–1.97
97.76–110.25 102/112 0.94 0.64–1.39 1.40 0.83–2.35 114/98 1.39 0.87–2.20 1.74 0.99–3.06
>110.25 88/97 0.98 0.64–1.50 2.01 0.95–4.29 109/109 1.08 0.68–1.72 1.64 0.77–3.50
p for trend 0.84 0.08 0.61 0.14
Hip circumference (cm)
≤103.18 120/134 Ref Ref 76/81 Ref Ref
103.19–111.63 129/107 1.28 0.88–1.86 1.60 1.06–2.41 89/98 1.06 0.68–1.68 1.14 0.70–1.86
111.64–123.15 95/113 0.97 0.65–1.43 1.50 0.91–2.46 112/98 1.31 0.84–2.04 1.47 0.85–2.56
>123.15 97/109 1.10 0.74–1.65 2.78 1.32–5.88 90/96 0.97 0.61–1.54 1.22 0.56–2.62
p for trend 0.92 0.02 0.92 0.65
*BMI measured at interview.
OR1: Adjusted for age, ethnicity, country of origin (United States, Caribbean, other), education, family history of breast cancer, history of benign breast disease,
age at menarche, age at menopause (for postmenopausal women), parity (continuous), breastfeeding (yes/no), age at first birth, OC use (ever/never). OR2: BMI
further adjusted for waist circumference. Percent body fat, waist circumference and hip circumference, further adjusted for BMI. Percent body fat adjusted for
years since menopause instead of age at menopause.
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http://www.biomedcentral.com/1471-2407/13/475because the component of weight due to fatness is
accounted for by abdominal circumference [31]. Therefore,
the evaluation of waist circumference adjusted for BMI
may be a better assessment of the association with adipo-
sity. Given this, it makes sense that the effect of adjusting
for BMI was more pronounced in premenopausal women,
who tend to have more lean mass.
The role of body composition on breast cancer risk
has received little attention, particularly among AA
women and, to our knowledge, we are the first study
to evaluate it and found no significant associations. It
should be noted that we used bioelectrical impedance tomeasure body composition, which is not as precise as
other methods, such as dual energy x-ray absorptiometry
(DXA) and computed axial tomography (CAT) [32].
Therefore, our methods may have led to some degree of
random misclassification in body composition measures
that may have hampered our ability to detect an associ-
ation. We are also aware that breast cancer treatment
and menopause may affect body composition [32]. In-
creases in body fat and decreases in lean body mass after
breast cancer treatment have been reported in studies,
but not consistently, and these changes are not easily
separated from those occurring with the aging process
Table 6 Association of body size with premenopausal breast cancer by hormone receptor status
ER+/PR+ vs. controls ER-/PR- vs. controls ER-/PR- cases vs. ER+/PR+ cases
CO CA OR 95% CI CA OR 95% CI OR 95% CI
Current BMI*
Underweight/Normal (<25) 103 42 Ref 20 Ref Ref
Overweight (25–29.99) 142 58 1.15 0.67–1.96 31 1.17 0.59–2.34 1.05 0.47–2.37
Obese (≥30) 237 95 1.34 0.68–2.68 51 1.26 0.53–3.00 0.88 0.30–2.54
p for trend 0.40 0.65 0.74
% Body fat
≤35.9 137 62 Ref 20 Ref Ref
36–41.6 118 51 0.99 0.59–1.64 26 1.20 0.61–2.34 1.23 0.58–2.64
41.7–46.5 104 43 1.10 0.59–2.05 21 1.28 0.58–2.86 1.17 0.47–2.92
>46.5 106 30 0.91 0.37–2.24 24 1.78 0.59–5.37 1.68 0.47–6.08
p for trend 0.96 0.36 0.52
Waist to hip ratio
≤0.82 144 56 Ref 20 Ref Ref
0.83–0.87 120 48 0.99 0.60–1.63 27 1.13 0.61–2.10 1.20 0.58–2.49
0.88–0.92 121 45 1.06 0.63–1.78 23 1.02 0.52–2.00 0.97 0.44–2.15
>0.92 93 43 1.33 0.76–2.32 24 1.51 0.74–3.05 1.30 0.57–3.00
p for trend 0.33 0.32 0.63
Waist circumference (cm)
≤87.88 143 57 Ref 20 Ref Ref
87.89–97.75 119 52 1.28 0.76–2.17 24 1.07 0.55–2.10 0.80 0.37–1.75
97.76–110.25 116 47 1.57 0.80–3.08 25 1.52 0.67–3.47 0.78 0.28–2.16
>110.25 100 36 2.05 0.79–5.35 23 1.91 0.59–6.13 0.73 0.17–3.08
p for trend 0.13 0.25 0.67
Hip circumference (cm)
≤103.18 138 55 Ref 20 Ref Ref
103.19–111.63 111 52 1.50 0.89–2.54 33 2.25 1.16–4.37 1.36 0.61–3.00
111.64–123.15 116 40 1.69 0.89–3.20 22 1.65 0.73–3.73 0.75 0.28–1.99
>123.15 113 46 3.59 1.43–9.03 24 2.60 0.79–8.54 0.47 0.12–1.95
p for trend 0.01 0.22 0.15
*BMI measured at interview.
Abbreviations: CO number of controls, CA number of cases, ER estrogen receptor, PR progesterone receptor.
Adjusted for age, ethnicity, country of origin (United States, Caribbean, other), education, family history of breast cancer, history of benign breast disease, age at
menarche, parity (continuous), breastfeeding (yes/no), age at first birth, HRT use (ever/never), OC use (ever/never). BMI also adjusted for waist circumference.
Percent body fat, waist circumference, and hip circumference, also adjusted for BMI.
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http://www.biomedcentral.com/1471-2407/13/475[32]. For example, it is not certain whether these changes
in adiposity found in some studies could be attributed to
chemotherapy, or could be due to ovarian failure caused
by chemotherapy in premenopausal women [32] or to
behavioral changes after breast cancer diagnosis. We ad-
justed analyses of body composition for age and years
since menopause, but were not able to adjust for years
since ovarian failure in pre-menopausal women.
Our findings generally confirm the small but growing
body of literature suggesting that obesity may have a dif-
ferent impact on AA compared to EA women. The asso-
ciation of BMI with body fatness varies by age, gender,and race/ethnicity [33]. Body weight and BMI measures
may not capture variations of fat mass and lean mass
among women. In fact, for a given BMI, AA women
tend to have higher lean mass and lower fat than white
women [33]. Therefore, for AA women, waist and hip
circumferences and percent body fat may reflect adipo-
sity better than BMI and this may explain some of our
findings. For example, higher waist circumference has
been associated with insulin resistance and higher levels
of IGF-I compared to general obesity, which is linked
to higher levels of estrogens among postmenopausal
women [9]. It is possible that central and general obesity
Table 7 Association of body size with postmenopausal breast cancer by hormone receptor status
ER+/PR+ vs. controls ER-/PR- vs. controls ER-/PR- cases vs. ER+/PR+ cases
CO CA OR 95% CI CA OR 95% CI OR 95% CI
Current BMI*
Underweight/Normal (<25) 68 26 Ref 20 Ref Ref
Overweight (25-29.99) 132 49 1.05 0.55–1.98 34 0.77 0.38–1.59 0.88 0.36–2.13
Obese (≥30) 276 131 1.04 0.50–2.18 47 0.37 0.15–0.96 0.42 0.14–1.25
p for trend 0.95 0.03 0.07
% Body fat
≤35.9 94 34 Ref 23 Ref Ref
36–41.6 107 39 1.04 0.57–1.89 29 1.41 0.70–2.85 1.37 0.58–3.22
41.7–46.5 124 62 1.38 0.74–2.58 19 0.70 0.30–1.62 0.57 0.21–1.52
>46.5 119 57 1.39 0.62–3.12 25 1.39 0.49–3.99 1.11 0.33–3.73
p for trend 0.32 0.92 0.75
Waist to hip ratio
≤0.82 93 25 Ref 18 Ref Ref
0.83–0.87 117 57 1.71 0.95–3.07 26 1.12 0.56–2.26 0.65 0.26–1.57
0.88–0.92 116 53 1.55 0.85–2.81 17 0.61 0.28–1.33 0.36 0.14–0.95
>0.92 144 70 1.61 0.90–2.90 39 1.26 0.63–2.50 0.63 0.27–1.50
p for trend 0.27 0.63 0.38
Waist circumference (cm)
≤87.88 94 36 Ref 23 Ref Ref
87.89–97.75 118 39 0.88 0.48–1.60 25 0.93 0.45–1.92 1.14 0.48–2.73
97.76–110.25 121 56 1.30 0.68–2.48 25 1.11 0.48–2.57 0.95 0.36–2.45
>110.25 137 74 1.55 0.68–3.55 27 1.08 0.35–3.31 0.59 0.17–2.03
p for trend 0.20 0.83 0.34
Hip circumference (cm)
≤103.18 99 47 Ref 24 Ref Ref
103.19–111.63 126 42 0.72 0.40–1.28 33 1.29 0.64–2.59 2.10 0.90–4.89
111.64–123.15 122 56 0.91 0.48–1.72 23 1.06 0.45–2.48 1.43 0.51–4.03
>123.15 123 60 0.73 0.31–1.73 20 1.00 0.31–3.29 1.89 0.45–7.98
p for trend 0.65 0.81 0.61
*BMI measured at interview.
Abbreviations: CO number of controls, CA number of cases, ER estrogen receptor, PR progesterone receptor.
Adjusted for age, ethnicity, country of origin (United States, Caribbean, other), education, family history of breast cancer, history of benign breast disease,
age at menarche, age at menopause (for postmenopausal women), parity (continuous), breastfeeding (yes/no), age at first birth, HRT use (ever/never), OC use
(ever/never). BMI also adjusted for waist circumference. Percent body fat, waist circumference, and hip circumference, also adjusted for BMI. For postmenopausal
women, percent body fat adjusted for years since menopause instead of age at menopause.
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http://www.biomedcentral.com/1471-2407/13/475play different roles in AA and EA because the relative
role of hormonal pathways may be different in the two
groups. For example, consistent with other studies, the
Multi-Ethnic Cohort Study found lower postmenopausal
breast cancer rates in AA compared to white women,
but endogenous estrogen levels were found to be signifi-
cantly higher among AA, suggesting that estrogens may
play a less significant role on breast cancer etiology
among them [34]. Furthermore, a cross-sectional study
among AA pre-menopausal women found that upper
body fat distribution (WHR > 0.8) was a better markerfor a high risk hormonal profile (high estrogens, andro-
gens, and prolactin, and low sex hormone binding
globulin) for breast cancer than general obesity [35].
Case–control studies are subjected to well-known li-
mitations such as recall bias and selection bias. It is well
known that women tend to underestimate weight and
overestimate height, which could affect BMI computa-
tion. However, for the main variables under investigation
we did not rely on participants’ recall and, instead,
objective body measurements were taken. Case–control
studies are also prone to selection bias if the participating
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http://www.biomedcentral.com/1471-2407/13/475controls are not representative of the source population
that gave rise to cases. To improve participation among
AA controls, we supplemented RDD recruitment for AA
women in NJ with community recruitment. Community-
based recruitment was efficient in recruiting participants
and even some cases and RDD controls who refused to
participate in our study when they were first approached,
called us to do it after they saw the study advertised in
their communities (e.g., churches). This gave us some
reassurance that the three groups (cases, RDD controls,
and community controls) came from the same source
population [11]. Another limitation in our study is that we
did not have information on obesity-related comorbidities
and, therefore, we were not able to adjust for them. To
some extent, this may have explained the association
found with abdominal obesity in premenopausal women.Conclusions
Our study contributes to the limited literature on BMI
and other measures of adiposity and breast cancer risk
in AA women. As more evidence accumulates on the re-
lationship between BMI and breast cancer, it is beco-
ming obvious that the association is not straightforward,
with obesity affecting differently the various subgroups
defined by age, race/ethnicity, hormone receptor status,
and use of exogenous hormones. For AA women, the
evidence remains scarce, but points to a different rela-
tionship from that reported in EA, suggesting possible
different mechanisms. Larger studies in AA women are
needed to further evaluate these issues, as well as evalu-
ate the effect by “intrinsic” subtypes (luminal A, luminal
B, basal-like and human epidermal growth factor recep-
tor 2-positive/estrogen receptor-negative), which were
suggested in one study to be affected differently by adi-
posity measures [36]. Future research is also needed to
address the possibility that obesity affects breast cancer
risk through its contribution to obesity-related comor-
bidities, including diabetes, which are more common
among AA breast cancer patients, possibly through over-
lapping biologic mechanisms underlying associations be-
tween obesity, comorbidities, and breast cancer risk.
In summary, we found that higher waist and hip circum-
ference were associated with increased risk of preme-
nopausal breast cancer. While we did not find increased
risk for general obesity, other studies have found that a
higher BMI is associated with more advanced disease at
diagnosis [37-39]. Therefore, maintenance of a healthy
weight should be a goal for all women, but particularly
for AA women. By doing so, they could improve their
chances of survival if they develop breast cancer, as well
as prevent other chronic diseases highly prevalent in this
population, such as type II diabetes and cardiovascular
disease [40].Abbreviations
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receptor; PR: Progesterone receptor; NHANES: National Health and Nutrition
Examination Survey; WCHS: Women’s Circle of Health Study; NJSCR: New
Jersey State Cancer Registry.
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